38 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
shares, stock or securities of such entity, the ability otherwise to elect a majority of the board of directors of such entity, the power to direct
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
as incurred when these expenditures relate to our research and development services and have no alternative future uses.
The majority of our third-party
6-K
kz330y 2eb0h3e32
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-3/A
y4yv74tr8rcut6dl3 j8
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
F-3/A
zjxf7oqycajvp
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
EX-99.2
njc6d6y2nwbtupe wy
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
zxfpmia bn7
15 Apr 22
Shelf registration (foreign)
5:27pm
20-F
EX-2.5
655lis7
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-1.1
po5egkcuwuarp4y 6pg
31 Mar 22
Annual report (foreign)
4:33pm
20-F
fcbe0 q5qwla
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
m1k6yjllvzsvmjle zcy
5 Jan 22
Current report (foreign)
5:24pm
6-K
2tx7 9bwqddurp0
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.2
zm59t9ylgtj
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.2
01nv172ou8du3pa
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
6-K
EX-99.1
henxbub
17 May 21
Connect Biopharma Announces First
5:27pm
424B4
8y9syh0
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1/A
jjhb1vp4
18 Mar 21
Registration statement (foreign) (amended)
6:15am